HIGHLIGHTS
- who: Pouya Dehghankelishadi from the (UNIVERSITY) have published the paper: Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects, in the Journal: (JOURNAL)
- what: The immuno-competent nature of the C57BL/6 syngeneic model used in this study provided the opportunity to investigate the radiation induced immune_response after bosutinib-HDL NPs treatment.
- how: In this work the 22A ApoA-1 mimicking peptide was used as peptide component.
- future: Due to the significance of any potential side effects in these organs more detailed toxicity studies combined with multiple dose treatment plans . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.